Oncology & Cancer
A novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient
Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral ...
Apr 11, 2016
0
12